Li Beiling, Hong Changze, Fan Zhiping, Cai Shumin, He Qinjun, Lan Xiaoqin, Lai Qintao, Ji Yali, Luo Wenfan, Li Junying, Cheng Xiao, Liu Miaoxia, Gu Yixiu, Lu Guanting, Li Shaochuan, Wang Yali, Weng Xing, Niu Xiaoyun, Liu Qifa, Jalan Rajiv, Chen Jinjun
Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
J Hepatol. 2023 Feb;78(2):322-332. doi: 10.1016/j.jhep.2022.10.008. Epub 2022 Oct 27.
BACKGROUND & AIMS: Although the effect of bacterial infection on cirrhosis has been well-described, the effect of non-hepatotropic virus (NHV) infection is unknown. This study evaluated the genome fragments of circulating microorganisms using metagenomic next-generation sequencing (mNGS) in individuals with acute decompensation (AD) of cirrhosis, focusing on NHVs, and related the findings to clinical outcomes.
Plasma mNGS was performed in 129 individuals with AD of cirrhosis in the study cohort. Ten healthy volunteers and 20, 39, and 81 individuals with stable cirrhosis, severe sepsis and hematological malignancies, respectively, were enrolled as controls. Validation assays for human cytomegalovirus (CMV) reactivation were performed in a validation cohort (n = 58) and exploratory treatment was instituted.
In the study cohort, 188 microorganisms were detected in 74.4% (96/129) of patients, including viruses (58.0%), bacteria (34.1%), fungi (7.4%) and chlamydia (0.5%). A NHV signature was identified in individuals with AD, and CMV was the most frequent NHV, which correlated with the clinical effect of empirical antibiotic treatment, progression to acute-on-chronic liver failure, and 90-day mortality. The NHV signature in individuals with acute-on-chronic liver failure was similar to that in those with sepsis and hematological malignancies. CMV was detected in 24.1% (14/58) of patients in the validation cohort. Of the 14 cases with detectable CMV by mNGS, nine were further validated by real-time PCR or pp65 antigenemia testing. Three patients with CMV reactivation received ganciclovir therapy in an exploratory manner and experienced clinical resolutions.
The results of this study suggest that NHVs may play a pathogenic role in complicating the course of AD. Further validation is needed to define whether this should be incorporated into the routine management of individuals with AD of cirrhosis.
A non-hepatotropic virus (NHV) signature, which was similar to that in individuals with sepsis and hematological malignancies, was identified in individuals with acute decompensation of cirrhosis. The detected viral signature had clinical correlates, including clinical efficacy of empirical antibiotic treatment, progression to acute-on-chronic liver failure and short-term mortality. Cytomegalovirus reactivation, which is treatable, may adversely affect clinical outcomes in some individuals with decompensated cirrhosis. Routine screening for NHVs, especially cytomegalovirus, may be useful for the management of individuals with acute decompensation of cirrhosis.
尽管细菌感染对肝硬化的影响已有充分描述,但非嗜肝病毒(NHV)感染的影响尚不清楚。本研究使用宏基因组下一代测序(mNGS)评估肝硬化急性失代偿(AD)患者循环微生物的基因组片段,重点关注NHV,并将结果与临床结局相关联。
对研究队列中的129例肝硬化AD患者进行血浆mNGS检测。分别纳入10名健康志愿者以及20例、39例和81例稳定期肝硬化、严重脓毒症和血液系统恶性肿瘤患者作为对照。在一个验证队列(n = 58)中进行了人巨细胞病毒(CMV)再激活的验证试验,并开展了探索性治疗。
在研究队列中,74.4%(96/129)的患者检测到188种微生物,包括病毒(58.0%)、细菌(34.1%)、真菌(7.4%)和衣原体(0.5%)。在AD患者中鉴定出NHV特征,CMV是最常见的NHV,其与经验性抗生素治疗的临床效果、进展为慢加急性肝衰竭以及90天死亡率相关。慢加急性肝衰竭患者的NHV特征与脓毒症和血液系统恶性肿瘤患者相似。在验证队列中,24.1%(14/58)的患者检测到CMV。在14例通过mNGS检测到可检测CMV的病例中,9例通过实时PCR或pp65抗原血症检测进一步得到验证。3例CMV再激活患者接受了更昔洛韦试验性治疗并实现临床缓解。
本研究结果表明,NHV可能在使AD病程复杂化中起致病作用。需要进一步验证以确定是否应将其纳入肝硬化AD患者的常规管理中。
在肝硬化急性失代偿患者中鉴定出一种与脓毒症和血液系统恶性肿瘤患者相似的非嗜肝病毒(NHV)特征。检测到的病毒特征与临床相关,包括经验性抗生素治疗的临床疗效、进展为慢加急性肝衰竭和短期死亡率。可治疗的巨细胞病毒再激活可能对一些失代偿期肝硬化患者的临床结局产生不利影响。对NHV进行常规筛查,尤其是巨细胞病毒,可能有助于肝硬化急性失代偿患者的管理。